Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL883853 | 0.88 | PTGDR2 (0.49) | PTGDR2PTGDRCA5ACYP1A2 | |
| SCHEMBL2066101 | 0.84 | PTGDR2 (0.45) | PTGDR2PTGDRCA5ACYP1A2ALDH1A1 | |
| SCHEMBL10121181 | 0.83 | PTGDR2 (0.46) | PTGDR2PTGDRNR3C1 | |
| SCHEMBL2065744 | 0.83 | CYP1A2 (0.43) | PTGDR2PTGDRCA5ACYP1A2 | |
| SCHEMBL883829 | 0.78 | PTGDR2 (0.51) | PTGDR2PTGDRSCN9ANR3C1 | |
| SCHEMBL883838 | 0.78 | NR3C1 (0.42) | PTGDR2NR3C1 | |
| SCHEMBL2066559 | 0.78 | PTGDR2 (0.48) | PTGDR2PTGDRCA5AALDH1A1CA2 | |
| SCHEMBL883831 | 0.77 | EPAS1 (0.47) | PTGDR2PTGDRNR3C1 | |
| SCHEMBL2065216 | 0.76 | PTGDR2 (0.49) | PTGDR2PTGDR | |
| SCHEMBL2066482 | 0.75 | PTGDR2 (0.49) | PTGDR2PTGDRCA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148572-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | claimed |
| US-20090192163-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | claimed |
| EP-1937632-A1 | NOVEL COMPOUNDS | Astra Zeneca AB (SE) | 2008-07-02 | — | — | EP | claimed |
| WO-2007039736-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | claimed |
| US-8148572-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-8148572-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-8148572-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-20090192163-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192163-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192163-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| EP-1937632-A1 | NOVEL COMPOUNDS | Astra Zeneca AB (SE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007039736-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039736-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192163-A1 | Novel Compounds | PAH, PC, DDC | PTGDR2 1000/4885PTGDR 859/4885CA5A 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.